The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
Disclosed herein are novel compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), useful in treating diseases in which cholesterol is implicated, including cardiovascular diseases.
The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
Disclosed herein are methods treating hypertriglyceridemia by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount effective to decrease the amount of serum triglyceride by at least 10% after the administering as compared to prior to the administering.
The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
The present disclosure provides methods and compositions for treating or preventing a sickle cell disease (SCD). The SCD may include sickle cell anemia (SCA). The method may include administering a composition such as a cyclodextrin to a subject in need of SCD treatment. Some embodiments include contacting a RBC with a cyclodextrin.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
10.
SYSTEMS AND METHODS FOR MANUFACTURING HYDROXYPROPYL-BETA-CYCLODEXTRIN
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
Provided herein is a modular system for the production of pharmaceuticals. The system's modular design allows for customization and efficient operation of the system, as well as the ability to deliver pharmaceuticals on demand.
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
12.
SYSTEMS AND METHODS FOR MANUFACTURING HYDROXYPROPYL-BETA-CYCLODEXTRIN
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
Provided herein are methods for the enzymatic production of alpha- cyclodextrin from sucrose. The methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to alpha-cyclodextrin. The methods produce higher yields of alpha-cyclodextrin relative to beta-cyclodextrin, gamma-cyclodextrin, or both.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Provided herein are methods for the enzymatic production of beta-cyclodextrin from sucrose. In some cases, the methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to beta-cyclodextrin. In some cases, the methods produce higher yields of beta-cyclodextrin relative to alpha-cyclodextrin, gamma-cyclodextrin, or both.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Provided herein are methods for the enzymatic production of gamma-cyclodextrin from sucrose. In some cases, the methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to gamma-cyclodextrin. In some cases, the methods produce higher yields of gamma-cyclodextrin relative to alpha-cyclodextrin, beta-cyclodextrin, or both.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Provided herein are methods for the enzymatic production of alpha-cyclodextrin from sucrose. In some cases, the methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to alpha-cyclodextrin. In some cases, the methods produce higher yields of alpha-cyclodextrin relative to beta-cyclodextrin, gamma-cyclodextrin, or both.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Provided herein are methods for the enzymatic production of beta-cyclodextrin from sucrose. In some cases, the methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to beta-cyclodextrin. In some cases, the methods produce higher yields of beta-cyclodextrin relative to alpha-cyclodextrin, gamma-cyclodextrin, or both.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Provided herein are methods for the enzymatic production of gamma-cyclodextrin from sucrose. In some cases, the methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to gamma-cyclodextrin. In some cases, the methods produce higher yields of gamma-cyclodextrin relative to alpha-cyclodextrin, beta-cyclodextrin, or both.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Provided herein are methods for the enzymatic production of alpha- cyclodextrin from sucrose. The methods involve contacting sucrose with one or more enzymes to convert sucrose to amylose, followed by contacting the amylose with one or more enzymes to convert the amylose to alpha-cyclodextrin. The methods produce higher yields of alpha-cyclodextrin relative to beta-cyclodextrin, gamma-cyclodextrin, or both.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Disclosed herein are methods alleviating or reducing inflammation and/or oxidative stress induced by oxidized LDL, reducing an amount (e.g., concentration) total cholesterol, reducing accumulation of total LDL, reducing an amount (e.g., concentration) of and/or a size (e.g., average size, maximum size) of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating familial hypercholesterolemia, reducing statin, cholesterol uptake inhibitor or PCSK9 inhibitor treatment, or reducing a frequency of, or delaying plasmapheresis treatment of a subject diagnosed with or suspected to have familial hypercholesterolemia. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
Disclosed herein are methods for reducing an amount of and/or a size of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
Disclosed herein are methods for preventing or reducing the risk of developing, and/or preventing or reducing the risk of an increase in an amount of and/or a size of, and/or changing the shape of, circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of preventing or reducing the risk of cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
25.
TREATMENT OF HYPERTRIGLYCERIDEMIA WITH 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
Disclosed herein are methods treating hypertriglyceridemia by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount effective to decrease the amount of serum triglyceride by at least 10% after the administering as compared to prior to the administering.
The present disclosure relates to compositions comprising mixtures of hydroxypropyl--cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl--cyclodextrins.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
Compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified, and methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
Disclosed herein are methods treating hypertriglyceridemia by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount effective to decrease the amount of serum triglyceride by at least 10% after the administering as compared to prior to the administering.
Disclosed herein are methods alleviating or reducing inflammation and/or oxidative stress induced by oxidized LDL, reducing an amount (e.g., concentration) total cholesterol, reducing accumulation of total LDL, reducing an amount (e.g., concentration) of and/or a size (e.g., average size, maximum size) of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating familial hypercholesterolemia, reducing statin, cholesterol uptake inhibitor or PCSK9 inhibitor treatment, or reducing a frequency of, or delaying plasmapheresis treatment of a subject diagnosed with or suspected to have familial hypercholesterolemia. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions, namely, acute bronchitis, allergies, arthritis, asthma, cancer, cellulitis, cirrhosis, common cold, cold sore, conjunctivitis, cystitis, diabetes, diarrhea, ear infection, fever, fibromyalgia, fungal infection, gastroenteritis, headaches, hemorrhoids, high cholesterol, hyperglycemia, hypoglycemia, indigestion, irritable bowel syndrome, influenza, laryngitis, lyme disease, meningitis, mononucleosis, osteoporosis, pneumonia, pyelonephritis, rosacea, sinusitis, skin abscess, stomach aches, and streptococcal pharyngitis Research and development of new products, pharmaceutical preparations, and medical devices; scientific, medical, and pharmaceutical research and development; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; Conducting research and clinical trials in the field of medicine, medical devices, and pharmaceuticals
32.
METHODS FOR THE PREVENTION OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS
Disclosed herein are methods for preventing or reducing the risk of developing, and/or preventing or reducing the risk of an increase in an amount of and/or a size of, and/or changing the shape of, circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of preventing or reducing the risk of cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
33.
METHODS FOR THE TREATMENT OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS
Disclosed herein are methods for reducing an amount of and/or a size of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
34.
METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS
Disclosed herein are methods treating atherosclerosis and/or atherosclerotic cardiovascular disease (e.g., coronary artery disease (CAD), peripheral artery disease (PAD), peripheral vascular disease (PVD), stroke, chronic kidney disease (CKD) caused by atherosclerosis, end-stage kidney disease (ESKD) caused by atherosclerosis, acute kidney failure caused by atherosclerosis, atherosclerotic renovascular disease (ARVD), renal artery stenosis, aortic aneurysm, idiopathic peripheral atrial hypertension, erectile dysfunction, intermittent claudication, post-surgical or iatrogenic arterial disease) by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount sufficient to increase a circulating and/or systemic level of one or more sterol or oxysterol in the subject compared to a baseline, an amount effective to increase a level of ABCA1 and/or ABCG1 in the subject compared to a baseline, an amount effective to increase a level of plasma cholesterol crystal dissolution capacity in the subject compared to a baseline, or any combination thereof.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
35.
METHODS FOR THE TREATMENT OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS
Disclosed herein are methods for reducing an amount of and/or a size of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
36.
METHODS FOR THE PREVENTION OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS
Disclosed herein are methods for preventing or reducing the risk of developing, and/or preventing or reducing the risk of an increase in an amount of and/or a size of, and/or changing the shape of, circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of preventing or reducing the risk of cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
37.
METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS
Disclosed herein are methods treating atherosclerosis and/or atherosclerotic cardiovascular disease (e.g., coronary artery disease (CAD), peripheral artery disease (PAD), peripheral vascular disease (PVD), stroke, chronic kidney disease (CKD) caused by atherosclerosis, end-stage kidney disease (ESKD) caused by atherosclerosis, acute kidney failure caused by atherosclerosis, atherosclerotic renovascular disease (ARVD), renal artery stenosis, aortic aneurysm, idiopathic peripheral atrial hypertension, erectile dysfunction, intermittent claudication, post-surgical or iatrogenic arterial disease) by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount sufficient to increase a circulating and/or systemic level of one or more sterol or oxysterol in the subject compared to a baseline, an amount effective to increase a level of ABCA1 and/or ABCG1 in the subject compared to a baseline, an amount effective to increase a level of plasma cholesterol crystal dissolution capacity in the subject compared to a baseline, or any combination thereof.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations. Medical devices. Research and development of new products, pharmaceutical
preparations, and medical devices; scientific, medical, and
pharmaceutical research and development; drug discovery
services; providing medical and scientific research
information in the field of medicine, medical devices, and
pharmaceuticals; scientific investigations for medical
purposes; conducting research and clinical trials in the
field of medicine, medical devices, and pharmaceuticals.
